Benzinga · Feb 17, 2026
TE
NASDAQ · TELO
Telomir Pharmaceuticals, Inc. Common Stock
Healthcare · Biotechnology
$1.13
Down-$0.01 (-0.88%)
Updated Sep 17, 2026, 10:48 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 50.71M
- P/E ratio
- -4.07
- Dividend yield
- 0.00%
- 52-week range
- $0.89 – $1.50
- Volume
- 37.95K
- Avg. volume
- 1.83M
Price performance
TELO price history
1M range · 20 trading sessions · Daily adjusted prices
TELO closed at $1.13 after 20 trading sessions, down 3.42% for the selected period.
- Last close
- $1.13
- Period change
- -3.42%
- Period low
- $1.10
- Period high
- $1.22
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.1437 | $1.1691 | $1.13 | $1.13 | 37.95K |
| Sep 15, 2026 | $1.16 | $1.1788 | $1.1401 | $1.17 | 27.41K |
| Sep 14, 2026 | $1.12 | $1.1975 | $1.115 | $1.17 | 50.05K |
| Sep 11, 2026 | $1.18 | $1.208 | $1.11 | $1.17 | 33.26K |
| Sep 10, 2026 | $1.19 | $1.22 | $1.175 | $1.18 | 32.47K |
| Sep 9, 2026 | $1.19 | $1.23 | $1.18 | $1.22 | 32.12K |
| Sep 8, 2026 | $1.14 | $1.2299 | $1.13 | $1.19 | 74.91K |
| Sep 4, 2026 | $1.17 | $1.19 | $1.16 | $1.16 | 33.92K |
| Sep 3, 2026 | $1.12 | $1.17 | $1.11 | $1.16 | 64.23K |
| Sep 2, 2026 | $1.11 | $1.13 | $1.0885 | $1.12 | 31.38K |
| Sep 1, 2026 | $1.13 | $1.13 | $1.085 | $1.10 | 19.57K |
| Aug 31, 2026 | $1.11 | $1.14 | $1.08 | $1.12 | 45.43K |
| Aug 28, 2026 | $1.20 | $1.20 | $1.14 | $1.14 | 38.24K |
| Aug 27, 2026 | $1.16 | $1.20 | $1.145 | $1.19 | 131.18K |
| Aug 26, 2026 | $1.17 | $1.20 | $1.1412 | $1.17 | 69.09K |
| Aug 25, 2026 | $1.18 | $1.196 | $1.156 | $1.18 | 40.83K |
| Aug 24, 2026 | $1.13 | $1.20 | $1.13 | $1.17 | 56.36K |
| Aug 21, 2026 | $1.13 | $1.16 | $1.1099 | $1.13 | 43.39K |
| Aug 20, 2026 | $1.18 | $1.18 | $1.11 | $1.13 | 35.3K |
| Aug 19, 2026 | $1.10 | $1.20 | $1.10 | $1.17 | 100.76K |
Latest TELO news
The latest Smart Investors Daily articles mentioning TELO.
Stock researchCompany · Overview
TELO research
Overview
Company profile and research snapshot.
Company profile
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Feb 5, 2026
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire ...
Benzinga · Feb 5, 2026
Telomir Pharmaceuticals Announces New Data Supporting Telomir-Zn's Mechanism In Cancer And Aging, Plans Submission For Investigational New Drug Application In Q1 2026
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.
accessnewswire.com · Nov 25, 2025
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November 25, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today reported new preclinical findings demonstrating that its lead therapeutic candidate, Telomir-1, reduced PSA (prostate-specific antigen) levels in androgen-responsive human prostate cancer cells (LNCaP).
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
